Loading...
•
Sep 30, 2023
Anika Q3 2023 Earnings Report
Reported third quarter financial results and raised full-year financial guidance on growing momentum across the business.
Key Takeaways
Anika Therapeutics reported strong third quarter results with revenue growth exceeding expectations. Joint Preservation and Restoration was up 14% and OA Pain Management was up 2%. The company also raised its overall revenue outlook for fiscal year 2023 to between $164 million and $166 million.
Delivered 14% growth in Joint Preservation and Restoration.
Experienced higher-than-expected growth in OA Pain Management.
Fully launched RevoMotion Reverse Shoulder System.
Received FDA clearance for Integrity Implant System and X-Twist Fixation System.
Forward Guidance
The Company has raised its overall revenue outlook for fiscal year 2023 to between $164 million and $166 million, representing growth of 5% to 6% compared to 2022, up from its previous range of $159.5 million to $163 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...